I agree that even conserative market penetration will generate enough for CYDY to be profitable and explore other indications. Your numbers may turn out to be accurate with some potential off label or higher penetration rates, but just wanted to point out that ~70% of the MDR 2/3 numbers you noted will be R5 strain......if using your same penetration assumptions it will lower to ~9,450 MDR3 at 50% and 17,200 MDR2 at 10%.

I don't understand how you calculated your earnings, but given my lower / revised 70% R5 numbers of ~26,600 patients, $50,000 annual costs, assuming 70% net sales, 60.5% royalty out (50% + 10.5%) and 80% profit margin I come up with $294m in earnings. So unless I am missing something or you used a lower cost (maybe $35k??), then even with the lower patient numbers my estimated earnings are higher.